[Transfusion in haematology].
In the field of oncohematology, the rationale for the use of blood transfusion relies both on the proliferative advantage of the transformed clone over the others and on hematologic toxicity of chemotherapy. In France, transfusion thresholds are established by a consensus conference organized by the Agence française de sécurité sanitaire des produits de santé (Afssaps), the French health products safety agency: 80g/l for PRC and 10G/l for platelets concentrates in patients without additional hemorragic risk factors. For FFP especially in TTP, thresholds are more patient-related. Transfusion for sickle cell patients remains a scientific challenge.
Renaudier
P
P
Unité d'hémovigilance, hôpital de la Croix-Rousse, Lyon, France. philippe.renaudier@chu-lyon.fr
D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000209:etiology / Q000628:therapy; D000755:Anemia, Sickle Cell / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016913:Blood Component Transfusion; D001803:Blood Transfusion / Q000331:legislation & jurisprudence / Q000592:standards; D019070:Cell Lineage; D002648:Child; D002999:Clone Cells / Q000473:pathology; D006402:Hematologic Diseases / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy; D013921:Thrombocytopenia / Q000139:chemically induced / Q000209:etiology / Q000628:therapy
D000970:Antineoplastic Agents